Debate: PRO position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?

American Journal of Nephrology

Volumn 31, Issue 6, 2010, Pages

  Singh, Ajay K ^a   Locatelli, Francesco ^b   Del Vecchio, Lucia ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIALYSIS; DRUG MEGADOSE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORTALITY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CHRONIC DISEASE; COMPLICATION; KIDNEY DISEASE; ARTICLE; BLOOD;

ANEMIA; CHRONIC DISEASE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; TREATMENT OUTCOME;

EID: 77952508045     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314628     Document Type: Note

References (0)